Current filters:  
Canada
Life Sciences, Biotechnology & Nanotechnology
Canada
Smart & Biggar
On November 20, 2019, the Federal Court (FC) issued its reconsideration decision on the quantum of damages owed by Apotex for its infringement of eight Eli Lilly process...
Norton Rose Fulbright Canada LLP
Health Canada received an ATI request for information on Fortekor.
Fasken
The Patented Medicine Prices Review Board recently published draft Guidelines to replace the current Compendium of Policies, Guidelines and Procedures, leading up to the coming into force of the amended ...
Fasken
In preparation for the coming into force of the amended Patented Medicines Regulations, the PMPRB has published draft guidelines to replace the current Compendium of Policies, Guidelines and Procedures.
Bereskin & Parr LLP
Biotechnology companies have a long road to commercialization. Investors, shareholders and company officials often have their patience tested
Norton Rose Fulbright Canada LLP
Not all software falls within the scope of the Act and Regulations.
Norton Rose Fulbright Canada LLP
The Canadian pharma and life sciences space saw many developments in 2019. These included major policy initiatives and regulatory changes affecting the industry, driven in part by three high-profile
Smart & Biggar
In 2019, Rx IP Update reported on a number of developments in Canadian life sciences IP and regulatory law. We review top developments below:...
Smart & Biggar
Innovative Medicines Canada (IMC) has announced changes to its Code of Ethical Practices for the first time since the last significant update in 2014.
Fasken
To begin, it is now explicit that the guiding principles apply throughout the IMC Code and should be read into all sections.
Smart & Biggar
The Federal Court had previously allowed a concurrent trial on common invalidity issues in actions under the Patented Medicines (Notice of Compliance) Regulations (PMNOC Regulations)...
Smart & Biggar
As previously reported, the Federal Court granted Teva's claim for compensation under section 8 of the Patented Medicines (Notice of Compliance) Regulations relating to Teva's bortezomib product...
Clark Wilson LLP
As the use of reproductive technologies becomes more mainstream, the law (which is often slow to catch up with science) is evolving to recognize the diverse ways in which people choose to grow ...
Miller Thomson LLP
A June 2019 Government of Canada report describes a disturbing trend of rising opioid-related deaths in Canada, a situation it called an opioid crisis.
Torys LLP
Final amendments to the Patented Medicines Regulations have been announced by the Government of Canada giving the Patented Medicine Prices Review Board
Miller Thomson LLP
Drugs and medical devices are integral parts of the Canadian health care system, used by many to treat and prevent a variety of conditions.
Smart & Biggar
On June 10, 2019, the Regulations Amending the Food and Drug Regulations (Serious Adverse Drug Reaction Reporting – Hospitals)and Regulations Amending the Medical Devices Regulations
Smart & Biggar
The Canadian Agency for Drugs and Technologies in Health (CADTH) released Issue 8 of its Pharmaceutical Reviews Update announcing updates
Smart & Biggar
On June 27, 2019, Health Canada published Drug and medical device highlights 2018: Helping you maintain and improve your health, an annual highlights report for 2018.
Norton Rose Fulbright Canada LLP
The Competition Bureau recently conducted a preliminary investigation into possible competition concerns arising from a proposal to include a clause in a procurement contract that would restrict off-label use of a vaccine.
FREE News Alerts
Sign Up for our free News Alerts - All the latest articles on your chosen topics condensed into a free bi-weekly email.
Upcoming Events
Tools
Font Size:
Translation
Mondaq Social Media